Skip to contentV
Vsee Health, Inc.
V
VSEEVsee Health, Inc. Q2 2025 · 10-Q
Revenue$1.06M$1.06M−38.3% vs Q2 2024 Net Income-$2.61M-$2.61MN/M vs Q2 2024 EPS Diluted-$0.16-$0.16N/M vs Q2 2024 Gross Profit$615,044−20.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vsee Health, Inc. · CIK 1864531 · Engraved from SEC EDGAR
Operating Cash Flowderived-$324,601N/M Free Cash Flowderived-$312,728N/M Margins · derivedGross margin58.3%+12.9 pt vs Q2 2024
Operating margin-147.5%−93.0 pt vs Q2 2024
Net margin-247.7%−210.6 pt vs Q2 2024
ended Jun 30, 2025 · filed Oct 15, 2025 · 107 d after period end